Neopharmed Gentili
Description
Neopharmed Gentili is an Italian pharmaceutical company specialized in the commercialization of high therapeutic value products and an important player in the national market.
In the last ten years Neopharmed has grown steadily thanks to extraordinary finance operations and the consolidation of collaborative relationships with important multinational players such as MSD, Organon, Teva, Bayer and Sanofi, which strengthen company’s image as a serious and dynamic enterprise, with a wide products portfolio in several therapeutic areas: vascular, cardio-metabolic, respiratory, osteoarticular, CNS, antibiotics, gastrointestinal, paediatrics, OTC products.
The company was already very active in M&A prior to the funds entrance, a process that is now accelerated thanks to enhanced scope and capabilities. Just to mention a few operations, in 2022 we concluded the acquisition of Minias (Lormetazepam) from Bayer in Italy and Japan, Tranquirit (Diazepam) from Sanofi in Italy, and of Valeas, an Italian company focused in respiratory and pediatrics.Neopharmed acquired worldwide rights to Antrolin (Nifedipine-Lidocaine) and is actively looking for partners that can market the product outside of Europe.
For the future, Neopharmed aims to expand beyond national borders with the goal of establishing a structure in major European countries.
